Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 51 references
Medicine
TL;DR
Evidence for pathogenic ILC2s in severe asthma provides a mechanistic framework linking chronic type 2 inflammation to persistent airway fibrosis, and therapeutic strategies targeting alarmins, cytokines, CDKs, and steroid-resistance signaling are discussed.
Abstract
Severe asthma is characterized by persistent airway inflammation, irreversible airway remodeling, and reduced responsiveness to glucocorticoids. Subepithelial fibrosis, a major determinant of progressive lung function decline, remains mechanistically undefined. Evidence identifies group 2 innate lymphoid cells (ILC2s) as key contributors to fibrotic airway remodeling. Importantly, ILC2s in severe asthma are not simply increased in number but functionally reprogrammed into a pathogenic, profibrotic state. We summarize evidence for pathogenic ILC2s and discuss three defining properties distinguishing them from homeostatic ILC2s. First, pathogenic ILC2s acquire a fibrogenic phenotype marked by increased IL-13, IL-4, IL-5, and amphiregulin, promoting fibroblast activation and matrix deposition. Second, they exhibit enhanced proliferative capacity driven by cell cycle-related (CDK4/6) and transcriptional (CDK8/19) cyclin-dependent kinases, expanding the pathogenic pool. Third, JAK–STAT5–Bcl-xL and PI3K–Akt–mTORC1 signaling confers resistance to glucocorticoid-induced apoptosis, enabling persistence despite corticosteroid therapy. Together, these properties provide a mechanistic framework linking chronic type 2 inflammation to persistent airway fibrosis. We also discuss therapeutic strategies targeting alarmins, cytokines, CDKs, and steroid-resistance signaling, and highlight open questions on ILC2 heterogeneity. Future single-cell and spatial transcriptomic studies will determine whether these properties arise within a common ILC2 population or distinct subsets, informing precision therapies for severe asthma.
A CD28-JAK1/STAT6-Th2-monocyte-derived alveolar macrophage pathway is defined as a mechanistic driver of pulmonary fibrosis and nominate CD28 and STAT6 as actionable immunologic targets that could complement existing antifibrotic therapies.
Yudai Miyashita, T. Kaiho, Raul Piseaux Aillon et al.· American Journal of Respirat...· 0 citations
Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity lung disease driven predominantly by type 2 immune responses. However, the classical immunological paradigm fails to adequately explain the persistent airway structural damage and frequent relapses observed even after inflammatory control is a...
Meng-Lin Li, Chen-Xiao Qiao, Yun Pan et al.· Frontiers in Allergy· 0 citations
The concept that T cells in IPF adopt nonclassical activation patterns that are driven by epithelial interactions within the fibrotic microenvironment is supported.
A. Serezani, J. Bazzano, B. Pascoalino et al.· JCI Insight· 0 citations
Asthma is a chronic airways disorder characterized by reversible airflow limitation that is variable, airway hyperresponsiveness and bronchial inflammation and is associated with symptoms of wheeze, cough and productive mucus. Asthma can be phenotyped based on airway inflammation, where eosinophilic asthma is the most...
Takahiro Matsuyama, Nahal Emami Fard, Akimichi Nagashima et al.· Frontiers in Immunology· 0 citations
BACKGROUND
Allergic asthma is a prevalent Th2-driven chronic inflammatory airway disease. While lung fibroblasts and fibroblast-derived IL-33 critically regulate airway inflammation, the fibroblast-specific role of IL-33 and the therapeutic mechanism of the immune regulatory small-molecule KQS1 and nicotinamide (K + N)...
Xiang-Dong Sun, Yuan-Yi Zhang, Ya-Dong Zheng et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.